BioMarin Pharmaceutical Inc. Stock price

Equities

BMRN

US09061G1013

Pharmaceuticals

Market Closed - Nasdaq 04:30:01 2024-03-28 pm EDT 5-day change 1st Jan Change
87.34 USD -1.43% Intraday chart for BioMarin Pharmaceutical Inc. +3.84% -9.42%
Sales 2024 * 2.76B Sales 2025 * 3.15B Capitalization 16.48B
Net income 2024 * 322M Net income 2025 * 493M EV / Sales 2024 * 5.61 x
Net cash position 2024 * 973M Net cash position 2025 * 1.35B EV / Sales 2025 * 4.81 x
P/E ratio 2024 *
52.9 x
P/E ratio 2025 *
33.5 x
Employees 3,401
Yield 2024 *
-
Yield 2025 *
-
Free-Float 99.32%
More Fundamentals * Assessed data
Dynamic Chart
Transcript : BioMarin Pharmaceutical Inc. Presents at Barclays 26th Annual Global Healthcare Conference 2024, Mar-12-2024 01:35 PM
BioMarin Pharmaceutical Says Voxzogo Leads to Height Gains in Children With Achondroplasia MT
Transcript : BioMarin Pharmaceutical Inc. Presents at Leerink Partners Global Biopharma Conference 2024, Mar-11-2024 10:40 AM
Biomarin Pharmaceutical Insider Sold Shares Worth $348,280, According to a Recent SEC Filing MT
BioMarin Pharmaceutical Appoints Cristin Hubbard as Chief Commercial Officer MT
Biomarin Announces Board Changes, Effective May 20, 2024 CI
Transcript : BioMarin Pharmaceutical Inc. Presents at TD Cowen 44th Annual Health Care Conference 2024, Mar-05-2024 12:50 PM
BioMarin Pharmaceutical Gets DOJ Subpoena for Documents Related to Vimizim, Naglazyme -- Update DJ
BioMarin Pharma gets DOJ subpoena on sponsored testing programs for two therapies RE
BioMarin Pharmaceutical Gets DOJ Subpoena for Documents Related to Vimizim, Naglazyme DJ
BioMarin Pharma gets DOJ subpoena on certain drug testing programs RE
Wedbush Adjusts BioMarin Pharmaceutical's PT to $80 From $78, Keeps Neutral Rating; Continues to See Limited Upside MT
Transcript : BioMarin Pharmaceutical Inc., Q4 2023 Earnings Call, Feb 22, 2024
BioMarin Pharmaceutical Q4 Adjusted Earnings, Revenue Rise, 2024 Outlook Set -- Shares Decline After Hours MT
BioMarin Pharmaceutical Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023 CI
More news
1 day-1.43%
1 week+3.04%
Current month+1.23%
1 month-3.68%
3 months-10.77%
6 months-3.35%
Current year-9.42%
More quotes
1 week
83.90
Extreme 83.895
88.74
1 month
83.44
Extreme 83.44
89.00
Current year
83.44
Extreme 83.44
99.25
1 year
76.02
Extreme 76.02
100.38
3 years
70.73
Extreme 70.73
117.77
5 years
62.88
Extreme 62.88
131.95
10 years
55.04
Extreme 55.04
151.75
More quotes
Managers TitleAgeSince
Chief Executive Officer 56 Nov. 30
Director of Finance/CFO 50 02-11-30
Chief Tech/Sci/R&D Officer - 20-10-04
Members of the board TitleAgeSince
Director/Board Member 70 16-01-03
Director/Board Member 70 05-05-15
Chairman 65 06-12-13
More insiders
Date Price Change Volume
24-03-28 87.34 -1.43% 1,027,708
24-03-27 88.61 +0.99% 1,031,697
24-03-26 87.74 +1.41% 1,346,939
24-03-25 86.52 +1.63% 1,409,254
24-03-22 85.13 +1.21% 876,820

Delayed Quote Nasdaq, March 28, 2024 at 04:30 pm EDT

More quotes
BioMarin Pharmaceutical Inc. (BioMarin) is a biotechnology company, which is engaged in developing and commercializing therapies that address the root cause of genetic conditions. BioMarin's commercial products include Vimizim (elosulfase alpha), Naglazyme (galsulfase), Palynziq (pegvaliase-pqpz), Brineura (cerliponase alfa), Aldurazyme (laronidase), Roctavian (valoctocogene roxaparvovec), Kuvan (sapropterin dihydrochloride), and Voxzogo (vosoritide). Vimizim is an enzyme replacement therapy for the treatment of MPS IVA, a lysosomal storage disorder. The Roctavian is an adeno associated virus (AAV5) vector gene therapy designed to restore factor VIII plasma concentrations in patients with severe hemophilia A. Voxzogo is a once daily injection analog of C-type Natriuretic Peptide (CNP) for the treatment of achondroplasia. Brineura is a recombinant human tripeptidyl peptidase 1 (TPP1) for the treatment of patients with CLN2, a form of Batten disease.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
30
Last Close Price
87.34 USD
Average target price
109.8 USD
Spread / Average Target
+25.75%
Consensus
  1. Stock
  2. Equities
  3. Stock BioMarin Pharmaceutical Inc. - Nasdaq